公开(公告)号：US12121626B2

公开(公告)日：2024-10-22

申请号：US17542473

申请日：2021-12-05

Applicant: Zhejiang University

Inventor： Mingying Yang ,  Fang Lei ,  Yajun Shuai

IPC: A61K38/10 ,  A61L24/00 ,  A61L24/10

CPC classification number: A61L24/108 ,  A61L24/0015 ,  A61L2300/252 ,  A61L2300/418 ,  A61L2400/04

Abstract: The present invention discloses a blood coagulation-promoting silk fibroin-polypeptide electrospun membrane and a preparation method thereof. The electrospun membrane is made by using silkworm silk fibroin as a carrier and adding the polypeptide GPRPPSEHLQIT. It is mainly used for promoting blood coagulation, and is a blood coagulation material that can targetedly bind to human fibrinogen. The preparation method includes the steps of dissolving, filtering, dialyzing, concentrating and freeze-drying silkworm cocoons after degumming to obtain silk fibroin freeze-dried powder. The polypeptide used in the present invention is a polypeptide obtained by self-screening. Compared with other polypeptides, it can specifically targetedly bind to human fibrinogen.

公开(公告)号：US20240299616A1

公开(公告)日：2024-09-12

申请号：US18665926

申请日：2024-05-16

Applicant: ABC IP, LLC

Inventor： Mladen Thomas Strbac

IPC: A61L24/00 ,  A61L24/04 ,  F41A17/48 ,  F41A19/10 ,  F41A19/15 ,  F41A19/24

CPC classification number: A61L24/0036 ,  A61L24/0015 ,  A61L24/043 ,  F41A17/48 ,  F41A19/10 ,  F41A19/15 ,  F41A19/24 ,  A61L2300/252 ,  A61L2300/418 ,  A61L2400/04 ,  A61L2430/36

Abstract: A trigger mechanism that can be used in AR-pattern firearms has a hammer, a trigger member, a disconnector, a locking member, and a “three position” safety selector having safe, standard semi-automatic, and forced reset semi-automatic positions. In the standard semi-automatic position, rearward movement of the bolt carrier causes rearward pivoting of the hammer such that the disconnector hook catches the hammer hook, at which time a user must manually release the trigger member to free the hammer from the disconnector to permit the hammer and trigger member to pivot to the set positions so that the user can pull the trigger member to fire the firearm. In the forced reset semi-automatic position, rearward movement of the bolt carrier causes rearward pivoting of the hammer causing the trigger member to be forced to the set position, the safety selector preventing the disconnector hook from catching the hammer hook, and thereafter when the bolt carrier reaches the substantially in-battery position the user can pull the trigger member to fire the firearm without manually releasing the trigger member. The locking member is pivotable between a first position at which the locking member mechanically blocks the trigger member from moving to the released position and a second position at which the locking member does not mechanically block the trigger member allowing the trigger member to be moved to the released position. The locking member is spring biased toward the first position and moved against the spring bias to the second position by contact from the bolt carrier during forward movement of the bolt carrier as the bolt carrier reaches a substantially in-battery position.

公开(公告)号：US20240277893A1

公开(公告)日：2024-08-22

申请号：US18644676

申请日：2024-04-24

Applicant: UAB Bioremedium

Inventor： Šiurkus Juozas

IPC: A61L26/00

CPC classification number: A61L26/008 ,  A61L26/0052 ,  A61L26/0066 ,  A61L26/0076 ,  A61L2300/252 ,  A61L2300/254 ,  A61L2300/402 ,  A61L2300/406 ,  A61L2300/41 ,  A61L2300/414 ,  A61L2300/418 ,  A61L2300/802

Abstract: Stabilized pharmaceutical wound dressing compositions comprising calreticulin protein for use in medical treatment, in particular for topical treatment of acute and chronic wounds, are provided. Pharmaceutical compositions of the present invention comprise calreticulin protein or a functional fragment or derivative thereof and one or more of pharmaceutically acceptable polymeric materials that form hydrogel. More specifically, compositions of present invention can be sprayed onto a wound as a liquid or applied topically in the form of gel. Compositions of the present invention may further comprise serum albumins, preservatives and additional biologically active molecules.

公开(公告)号：US20240197954A1

公开(公告)日：2024-06-20

申请号：US18390310

申请日：2023-12-20

Applicant: UAB Bioremedium

Inventor： Šiurkus Juozas

IPC: A61L26/00 ,  A61K38/19

CPC classification number: A61L26/0066 ,  A61K38/19 ,  A61L26/0052 ,  A61L26/0076 ,  A61L26/008 ,  A61L2300/252 ,  A61L2300/254 ,  A61L2300/402 ,  A61L2300/406 ,  A61L2300/41 ,  A61L2300/414 ,  A61L2300/418 ,  A61L2300/802

Abstract: Stabilized pharmaceutical wound dressing compositions comprising calreticulin protein for use in medical treatment, in particular for topical treatment of acute and chronic wounds, are provided. Pharmaceutical compositions of the present invention comprise calreticulin protein or a functionally active fragment or derivative thereof and one or more of pharmaceutically acceptable polymeric materials that form hydrogel. More specifically, compositions of present invention can be sprayed onto a wound as a liquid or applied topically in the form of gel. Compositions of the present invention may further comprise serum albumins, preservatives and additional biologically active molecules.

公开(公告)号：US11992482B2

公开(公告)日：2024-05-28

申请号：US15405453

申请日：2017-01-13

Applicant: Rilento Pharma, LLC

Inventor： Khashayar Kevin Neshat

IPC: A61K31/445 ,  A61K9/06 ,  A61K9/16 ,  A61K9/19 ,  A61K38/48 ,  A61K45/06 ,  A61L24/00 ,  A61P23/02

CPC classification number: A61K31/445 ,  A61K9/06 ,  A61K9/1647 ,  A61K9/19 ,  A61K38/4833 ,  A61K45/06 ,  A61L24/0015 ,  A61L24/0036 ,  A61L24/0094 ,  A61P23/02 ,  C12Y304/21005 ,  A61L2300/402 ,  A61L2300/404 ,  A61L2300/418

Abstract: A malleable sustained release formulation is created utilizing a local anesthetic wherein the composition is made sustained release by incorporating it into a bovine or porcine hemostatic agent. The composition is malleable enough to fit into a cavity such as a dental cavity and form the shape of the cavity. In addition to providing sustained release of the anesthetic, the composition also provides quicker reduction in bleeding.

公开(公告)号：US11903799B2

公开(公告)日：2024-02-20

申请号：US17510559

申请日：2021-10-26

Applicant: Brent Edward Mabey ,  Jennifer Bowen

Inventor： Brent Edward Mabey ,  Jennifer Bowen

IPC: A61F5/00 ,  A61F13/04 ,  A61L15/12 ,  A61F5/30 ,  A61F13/00

CPC classification number: A61F13/04 ,  A61F5/30 ,  A61L15/12 ,  A61F2013/00336 ,  A61L2300/402 ,  A61L2300/404 ,  A61L2300/418

Abstract: Semi-rigid bandages disclosed herein include a bandage structure layer with an embedded resin material. The resin material is formulated to cure when exposed to an activator such as air or water. Upon curing, the bandage hardens to a semi-rigid state that is harder and more rigid than conventional bandage materials found in household first-aid kits, yet less rigid than fiberglass-based orthopedic casts.

公开(公告)号：US20240042091A1

公开(公告)日：2024-02-08

申请号：US18205399

申请日：2023-06-02

Applicant: STRYKER EUROPEAN OPERATIONS HOLDINGS LLC

Inventor： Bhushan Chandrashekhar-Bhat ,  Robbert Arnold De Graaf

IPC: A61L15/28 ,  A61L15/64 ,  A61L15/44 ,  A61L15/26 ,  A61L15/42

CPC classification number: A61L15/28 ,  A61L15/64 ,  A61L15/44 ,  A61L15/26 ,  A61L15/425 ,  A61L2300/232 ,  A61L2300/418 ,  A61L2400/04 ,  A61L2300/236

Abstract: The invention is directed a hemostatic foam, to a process for preparing a biodegradable hemostatic foam, and to the use of said foam. The hemostatic foam comprises a blend of a chitosan hemostatic agent and a polymer, which polymer provides the foam with a porosity of 85-99% and a foam density of 0.01-0.2 g/cm3.

公开(公告)号：US11883554B2

公开(公告)日：2024-01-30

申请号：US17229121

申请日：2021-04-13

Applicant: Ethicon, Inc.

Inventor： Yi-Lan Wang ,  Leo B. Kriksunov

IPC: A61L24/04 ,  A61M11/00 ,  A61M5/19 ,  A61L24/00 ,  A61L26/00

CPC classification number: A61L24/043 ,  A61L24/001 ,  A61L24/0015 ,  A61L26/009 ,  A61L26/0033 ,  A61L26/0038 ,  A61L26/0061 ,  A61L26/0066 ,  A61M5/19 ,  A61M11/007 ,  A61L2300/418 ,  A61L2400/04 ,  A61L2400/06

Abstract: The present invention is directed to a hemostatic semi-solid paste material comprising a bioabsorbable carrier hemostatic material; and a supplemental hemostatic agent; wherein the paste material has an elongated form extending along a lengthwise axis with an aspect ratio of at least 3; wherein the paste is self-supporting and syringe extrudable; and wherein the supplemental hemostatic agent has a non-homogenous distribution profile across a cross-section taken across the lengthwise axis. In another aspect, the present invention relates to devices for forming and expressing the hemostatic material.

公开(公告)号：US20230277445A1

公开(公告)日：2023-09-07

申请号：US18001375

申请日：2021-06-10

Applicant: UMC Utrecht Holding B.V. ,  SentryX B.V.

Inventor： Susanna Piluso ,  Jasper Gerard Steverink ,  Floris Rudolf Van Tol ,  Raymond Michel Schiffelers ,  Bas Jeroen Oosterman ,  Joannes Jacobus Verlaan

IPC: A61K9/00 ,  A61K47/42 ,  A61K31/445 ,  A61L24/10 ,  A61L24/00

CPC classification number: A61K9/0024 ,  A61K31/445 ,  A61K47/42 ,  A61L24/0015 ,  A61L24/0031 ,  A61L24/104 ,  A61L2300/402 ,  A61L2300/418

Abstract: The present invention relates to an adhesive drug carrier comprising an injectable hydrogel comprising at least one medication, wherein the hydrogel comprises a (i) a protein-based polymer functionalized with a functionalization agent that is able to form guest-host interactions with oxidized P-cyclodextrin, cross-linked with (ii) an oxidized P-cyclodextrin (oβ-CD) as matrix and the at least one medication (iii), and wherein the hydrogel further comprises (iv) a protein-based polymer bearing quinone and/or catechol groups. The invention further relates to a method for its preparation and a method for treatment.

公开(公告)号：US20230263941A1

公开(公告)日：2023-08-24

申请号：US18174327

申请日：2023-02-24

Applicant: ThoraGenix Innovations, Inc.

Inventor： Fotios M. ANDREOPOULOS

IPC: A61L27/36 ,  A61L27/44 ,  A61L27/54 ,  A61L27/38

CPC classification number: A61L27/3608 ,  A61L27/365 ,  A61L27/3687 ,  A61L27/3691 ,  A61L27/3821 ,  A61L27/44 ,  A61L27/54 ,  A61L2300/402 ,  A61L2300/406 ,  A61L2300/418

Abstract: Systems, methods, and devices include techniques for generating and using a demineralized bone matrix (DBM)-gelatin matrix allograft material. The DBM-gelatin material can be used to form an implant (e.g., for sternal closure operations) and/or a gel (e.g., for wound/fracture treatment). A method for forming the implant or bone graft can include forming the DBM from an initial bone material; and mixing, in a solution, the DBM with a gelatin carrier to form a DBM-gelatin solution. The gelatin carrier can include an animal-based collagen, such as a porcine-based collagen or a bovine-based collagen. Additionally, the method of forming the bone graft can include performing a crosslinking reaction with the DBM-gelatin solution. The implant can be packaged in a sterile hydration container prior to use.